AEON Biopharma, Inc.

AEON Biopharma announced the presentation of new analytical and functional data at the American Headache Society's 68th Annual Scientific Meeting, supporting the biosimilarity of ABP-450 to BOTOX®. The data demonstrated highly similar biological activity across multiple analytical approaches, including LC-MS peptide mapping and the LD50 potency assay, with ABP-450 lots meeting predefined equivalence criteria. This strengthens the analytical foundation for ABP-450, which targets the over $3.0 billion U.S. therapeutic neurotoxin market, where BOTOX® is currently the sole approved treatment for chronic migraine.

AEON Biopharma, Inc. made a corporate presentation available detailing its strategy to develop ABP-450 as the first clinically substitutable therapeutic alternative to BOTOX®. The company aims to unlock a $3.5 billion neurotoxin market by pursuing full-label extrapolation under the FDA's 351(k) biosimilar pathway. The presentation highlights strong analytical data, including 100% amino acid sequence identity and genetic/formulation parity with BOTOX®, and outlines a clear regulatory path following positive FDA Type 2a feedback.

AEON Biopharma, Inc. reported a net loss of $11.8 million for the three months ended March 31, 2026, a significant increase from a $9.1 million net income in the prior year period. The company disclosed substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows. During the quarter, AEON completed the second closing of a PIPE financing, raising $4.2 million, and exchanged $15.0 million in convertible notes with Daewoong for common stock, a new $1.5 million convertible note, and warrants.

AEON Biopharma reported its first quarter 2026 financial results, including a net loss of $(11.793) million, a decrease from a net income of $9.095 million in Q1 2025. The company announced positive feedback from its FDA Type 2a meeting, supporting the analytical similarity strategy for its ABP-450 biosimilar program. AEON also significantly strengthened its balance sheet by completing a $6 million PIPE financing and a Daewoong note exchange, reducing outstanding debt by over 90%. Additionally, John Bencich was appointed as the new Chief Financial Officer, and the company's cash and cash equivalents of $6.2 million as of March 31, 2026, are expected to fund operations into Q3 2026.

AEON Biopharma, Inc. announced its 2026 Annual Meeting of Stockholders to be held on June 17, 2026, at its Irvine, California offices. Stockholders will vote on the election of two Class III directors, Marc Forth and Seongsoo Park, and the ratification of KPMG LLP as the independent registered public accounting firm for 2026. CEO Robert Bancroft expressed encouragement regarding the progress of ABP-450 and the company's focused strategy.

AEON Biopharma announced its Annual Shareholder Meeting will be held on June 17, 2026, at 10:00 am PT. The company also disclosed that its audited consolidated financial statements for the fiscal year ended December 31, 2025, included a going concern qualification from its independent registered public accounting firm. This qualification reflects the company's liquidity position, with cash and cash equivalents expected to fund operations into the third quarter of 2026.

AEON Biopharma received a notice from NYSE American indicating non-compliance with continued listing standards due to a stockholders' equity deficit of approximately $55 million as of December 31, 2025, and losses in three of the last four fiscal years. The company is already under a plan to regain compliance, and this notice is related to previously disclosed compliance status following year-end results.